MOLN Stock Analysis: Buy, Sell, or Hold?
MOLN - Molecular Partners AG American Depositary Shares
$3.93
-0.12 (-3.02%)
▼
5d:
-12.86%
30d:
-19.47%
90d:
-10.48%
WAIT
LOW Confidence
Analysis Updated: Mar 30, 2026 12:00 AM ET
Earnings: May 21, 2026
Get Alerted When MOLN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: MOLN is down 12.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: MOLN is down 12.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: MOLN is currently trading at $3.93, which is considered oversold relative to its 30-day fair value range of $4.32 to $5.00. From a valuation perspective, the stock is trading at a discount (Forward PE: -20.1) compared to its historical average (47.4). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, MOLN is in a uptrend. Immediate support is located at $3.71, while resistance sits at $4.80. Short-term momentum is weak, with the stock down 3.0% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $10.98 (+179.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, MOLN is in a uptrend. Immediate support is located at $3.71, while resistance sits at $4.80. Short-term momentum is weak, with the stock down 3.0% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $10.98 (+179.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$4.32 -
$5.00
Company Quality Score
43/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.0%)
- BULLISH: Trading 179.5% below Wall St target ($10.98)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Recommendation downgraded due to -12.9% 5-day decline - wait for stabilization
Fair Price Analysis
30-Day Fair Range
$4.32 -
$5.00
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$3.71
Resistance Level
$4.80
Current Trend
Uptrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-20.05
Wall Street Target
$10.98
(+179.5%)
Revenue Growth (YoY)
-100.0%
PE vs Historical
-20.1 vs 47.4
CHEAP
Share & Embed Analysis
Last updated: March 30, 2026 6:31 PM ET
Data refreshes hourly during market hours. Next update: 7:31 PM
Data refreshes hourly during market hours. Next update: 7:31 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MOLN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$449 | 56 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$873 | 56 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$33 | 45 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$101 | 60 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$224 | 57 HOLD |
